(-0.07%) 5 143.50 points
(-0.04%) 38 544 points
(0.01%) 17 906 points
(-0.29%) $82.39
(1.33%) $2.06
(-1.11%) $2 331.60
(-2.46%) $26.98
(-0.66%) $955.20
(0.22%) $0.934
(0.42%) $11.03
(0.24%) $0.798
(-0.25%) $93.07
Live Chart Being Loaded With Signals
PuraPharm Corporation Limited, an investment holding company, researches, develops, produces, and sells concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 13 000.00 |
Vidutinė apimtis | 53 974.00 |
Rinkos kapitalizacija | 288.39M |
EPS | HKD0 ( 2024-03-28 ) |
Last Dividend | HKD0.0191 ( 2017-05-31 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -2.70 |
ATR14 | HKD0 (0.00%) |
PuraPharm Corp Ltd Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
PuraPharm Corp Ltd Finansinės ataskaitos
Annual | 2023 |
Pajamos: | HKD406.86M |
Bruto pelnas: | HKD214.85M (52.81 %) |
EPS: | HKD-0.270 |
FY | 2023 |
Pajamos: | HKD406.86M |
Bruto pelnas: | HKD214.85M (52.81 %) |
EPS: | HKD-0.270 |
FY | 2022 |
Pajamos: | HKD448.07M |
Bruto pelnas: | HKD260.59M (58.16 %) |
EPS: | HKD-0.300 |
FY | 2021 |
Pajamos: | HKD659.59M |
Bruto pelnas: | HKD423.35M (64.18 %) |
EPS: | HKD-0.329 |
Financial Reports:
No articles found.
PuraPharm Corp Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.0840 | 2016-05-19 |
Last Dividend | HKD0.0191 | 2017-05-31 |
Next Dividend | HKD0 | N/A |
Payout Date | 2017-06-23 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | HKD0.103 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.73 | -- |
Div. Sustainability Score | 0.0346 | |
Div.Growth Potential Score | 1.387 | |
Div. Directional Score | 0.711 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3818.HK | Ex Dividend Knight | 2023-08-21 | Annually | 0 | 0.00% | |
1709.HK | No Dividend Player | 2023-09-13 | Annually | 0 | 0.00% | |
0737.HK | Ex Dividend Knight | 2023-09-21 | Semi-Annually | 0 | 0.00% | |
2289.HK | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% | |
1277.HK | Ex Dividend Knight | 2023-10-09 | Semi-Annually | 0 | 0.00% | |
0335.HK | Ex Dividend Knight | 2023-09-04 | Annually | 0 | 0.00% | |
6069.HK | Ex Dividend Junior | 2023-06-28 | Annually | 0 | 0.00% | |
1836.HK | Ex Dividend Knight | 2023-09-06 | Annually | 0 | 0.00% | |
0861.HK | Ex Dividend Junior | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
0012.HK | Ex Dividend Knight | 2023-09-04 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.261 | 1.500 | -5.21 | -7.82 | [0 - 0.5] |
returnOnAssetsTTM | -0.126 | 1.200 | -4.19 | -5.03 | [0 - 0.3] |
returnOnEquityTTM | -0.574 | 1.500 | -7.49 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.612 | 0.800 | -1.939 | -1.552 | [1 - 3] |
quickRatioTTM | 0.225 | 0.800 | -3.38 | -2.70 | [0.8 - 2.5] |
cashRatioTTM | 0.0827 | 1.500 | -0.652 | -0.978 | [0.2 - 2] |
debtRatioTTM | 0.478 | -1.500 | 2.04 | -3.06 | [0 - 0.6] |
interestCoverageTTM | -1.798 | 1.000 | -1.777 | -1.777 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.137 | 2.00 | 9.95 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.0818 | 2.00 | 9.96 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 2.63 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.528 | 1.000 | 4.53 | 4.53 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.121 | 1.000 | -4.42 | -4.42 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.134 | 1.000 | -0.367 | -0.367 | [0.2 - 2] |
assetTurnoverTTM | 0.482 | 0.800 | -0.119 | -0.0956 | [0.5 - 2] |
Total Score | 0.0346 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -2.72 | 1.000 | -0.376 | 0 | [1 - 100] |
returnOnEquityTTM | -0.574 | 2.50 | -4.81 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.0818 | 2.00 | 9.97 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.137 | 2.00 | 9.95 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00588 | 1.500 | -3.29 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.133 | 1.000 | 9.18 | 0 | [0.1 - 0.5] |
Total Score | 1.387 |
PuraPharm Corp Ltd
PuraPharm Corporation Limited, an investment holding company, researches, develops, produces, and sells concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Haveron, Oncozac, and Immuzac names. It also provides Chinese medicine clinic management system for general clinic management; and operates Chinese medicine clinics under the Nong's name that provide Chinese medicine services and concentrated Chinese medicine granules products. In addition, the company engages in the plantation and trading of raw Chinese herbs; and manufacture and sale of traditional Chinese medicine decoction pieces. Further, it provides modernized Chinese medicine services; and Chinese medical diagnostic services. The company sells its products to hospitals, healthcare institutions, and medicine practitioners, as well as operates an online store. It operates 43 Nong's clinics in Hong Kong and 1 Nong's clinic in Guangxi, China. The company was founded in 1998 and is headquartered in Tai Po, Hong Kong.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.